On August 23, 2024, SciSparc Ltd. announced it submitted an IND application to the FDA for a Phase IIb clinical trial of SCI-110, aimed at treating Tourette Syndrome. This filing is significant for the company's future developments.
AI Assistant
SCISPARC LTD
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.